Trial Profile
A Phase I, Single-Dose, Randomized, Parallel-Group, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Bioavailability of IV and SC MABT5102A in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Jun 2017
Price :
$35
*
At a glance
- Drugs Crenezumab (Primary) ; Crenezumab
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Genentech
- 21 Oct 2009 New trial record